Dermatology content commonly referenced by physicians includes a combination of clinical guidelines, pivotal trial data, targeted therapies, and validated severity instruments. The following 10-item framework reflects widely used sources that inform dermatologic care.

1. American Academy of Dermatology (AAD) Acne Guideline (2024) — The 2024 American Academy of Dermatology guideline for acne vulgaris presents 18 evidence-based recommendations and 5 good practice statements and makes strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, and oral isotretinoin.

2. AAD Adult Atopic Dermatitis (AD) Guideline Updates (2023 to 2025) — The AAD adult AD guidelines were updated in response to new evidence since the 2023, and early 2024 guidelines. The 2025  focused update explains that several novel therapies became available after the earlier guideline publications.

3. Joint AAD-National Psoriasis Foundation (NPF) Psoriasis Guideline — The Joint AAD-NPF psoriasis guideline series addresses the management and treatment of psoriasis across topical therapies, biologics, systemic nonbiologic therapies, phototherapy, comorbidities, and pediatric psoriasis.

4. POETYK PSO-2 Trial — In the Phase 3 POETYK PSO-2 trial, deucravacitinib achieved superiority to placebo on the coprimary end points of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment 0/1 at week 16 in patients with moderate to severe plaque psoriasis.

5. ARCADIA 1 and ARCADIA 2 — In replicate Phase 3 trials, nemolizumab plus background topical therapy improved inflammation and itch in adolescent and adult patients with moderate-to-severe AD.

6. Topical Retinoids for Acne — Topical retinoids remain among the strongly recommended acne therapies in the 2024 AAD guideline, and US Food and Drug Administration labeling states that trifarotene is indicated for topical treatment of acne vulgaris in patients aged 9 years and older.

7. Biologics for Moderate-to-Severe Psoriasis — A JAMA Dermatology meta-analysis found that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.

8. JAK Inhibitors in AD — The AAD adult systemic AD guideline includes strong recommendations for abrocitinib, baricitinib, and upadacitinib. US Food and Drug Administration labeling states that ruxolitinib cream is indicated for short-term and intermittent longer-term topical treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children aged 2 years and older whose disease is not adequately managed with prescription topical therapies or for whom those treatments are not appropriate.

9. PASI — The AAD psoriasis guideline page states that PASI is recommended for clinical trials rather than for clinical practice.

10. Eczema Area and Severity Index (EASI) — The Harmonising Outcome Measures for Eczema initiative identifies EASI as the core instrument for clinical signs in eczema trials, and EASI references describe it as a tool that scores extent and severity across four body regions.

Sources: Journal of the American Academy of Dermatology, American Academy of Dermatology Association, National Psoriasis Foundation, Bristol Myers Squibb, The Lancet, US Food and Drug Administration, JAMA Dermatology, Harmonising Outcome Measures for Eczema, Eczema Area and Severity Index, Daily Med/National Library of Medicine